Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + omega-3-acid ethyl esters
- Development stage
- Unknown
- Lead developer
- Samsung Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of the HMG-CoA reductase inhibitor **atorvastatin** and **omega-3-acid ethyl esters** (a concentrated mixture of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]). This specific combination is being investigated by **Samsung Medical Center** in the "Intensive Lipid Lowering and Omega-3 in ACS" clinical trial (NCT02178332) for patients with **acute coronary syndrome** (ACS). The treatment regimen evaluates the impact of intensive lipid-lowering therapy (atorvastatin 40mg) combined with high-dose omega-3 fatty acids (4g) on coronary atherosclerotic plaque composition, specifically aiming to reduce necrotic core volume and stabilize vulnerable plaques. Atorvastatin acts by inhibiting cholesterol synthesis in the liver, while omega-3 fatty acids primarily reduce triglyceride levels and exert anti-inflammatory effects through the activation of PPAR-alpha.
- Brand names
- LipitorOmacor
- Other names
- Atorvastatin plus Omega-3EPA + DHA + atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on atorvastatin + omega-3-acid ethyl esters.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + omega-3-acid ethyl esters.